EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The role of atropine in myopia control: insights into choroidal and scleral mechanisms

Longxiang Huang, Jingjin Zhang, Youfang Luo

Frontiers in Pharmacology · 20.03.2025 · 16

DOI: 10.3389/fphar.2025.1509196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 20.03.2025. Verfasst von Longxiang Huang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, we investigate the inhibitory effects of atropine on the progression of experimental myopia by targeting the functions of the choroid and sclera and exploring its potential therapeutic mechanisms. Form deprivation myopia (FDM) was induced in C57BL/6 mice, with treatment groups receiving atropine. We assessed the effects on ocular morphology, extracellular matrix (ECM) protein expression, choroidal and scleral thickness, and choroidal vascular index (CVI) through histopathology, immunofluorescence, and quantitative quantitative polymerase chain reaction (qPCR). In vitro , mouse scleral fibroblasts (MSFs) were treated with Na 2 S 2 O 4 to induce hypoxia, followed by atropine treatment. Atropine treatment significantly reduced axial elongation and ECM remodeling in FDM mice, as indicated by a decrease in collagen volume fraction. It restored choroidal and scleral thickness and increased CVI, suggesting improved microcirculation. Atropine also modulated ECM protein expression and reduced the hypoxia marker Hypoxia-Inducible Factor-1α (HIF-1α). In vitro , atropine protected MSFs from hypoxia-induced damage, preserved cytoskeletal integrity, and modulated key signaling pathways, including P53 and β-catenin. These findings suggest that atropine holds promise for controlling myopia progression by improving choroidal microcirculation, reducing scleral hypoxia, and regulating ECM remodeling, supporting its therapeutic application in myopia management.

Schlagwörter

Stichwörter der Autor:innen

atropinechoroidal microcirculationextracellular matrix remodelingmyopiascleral hypoxia

Autor:innen und Institutionen

  • Department of Ophthalmology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
  • Department of Ophthalmology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • Fujian Institute of Ophthalmology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
  • Fujian Provincial Clinical Medical Research Center of Eye Diseases and Optometry, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
  • Department of Rehabilitation, Fuzhou Second General Hospital, Fuzhou, China.

Zitieren

APA

Huang, L., Zhang, J., & Luo, Y. (2025). The role of atropine in myopia control: insights into choroidal and scleral mechanisms. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1509196

Vancouver

Huang L, Zhang J, Luo Y. The role of atropine in myopia control: insights into choroidal and scleral mechanisms. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1509196

BibTeX
@article{Huang2025,
  author = {Huang, Longxiang and Zhang, Jingjin and Luo, Youfang},
  title = {The role of atropine in myopia control: insights into choroidal and scleral mechanisms},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1509196}
}
Kostenlos starten →